BRAF Mutation Implications in Central Nervous System Tumors

The BRAF gene encodes a serine/threonine kinase that lies at a pivotal node of the mitogen-activated protein kinase (MAPK) signalling cascade. Activating mutations—most notably the V600E substitution—result in constitutive pathway activation, driving uncontrolled proliferation in a subset of central nervous system (CNS) tumours. These mutations are particularly prevalent in pleomorphic xanthoastrocytoma (PXA) and the epithelioid variant of glioblastoma, and occur at lower frequency in other gliomas and metastases. Molecular detection of BRAF V600E has transformed diagnostic precision, distinguishing PXA from other astrocytic neoplasms, and has become a routine screen in patients under 30 or with unusual histological features. Importantly, the presence of a targetable BRAF mutation has spurred the use of selective inhibitors—often combined with downstream MEK blockade—that can penetrate the blood–brain barrier and elicit rapid radiological and clinical responses. Ongoing research seeks to define resistance mechanisms, optimise combination regimens and integrate BRAF status into prognostic algorithms to guide personalised management across diverse CNS tumour subtypes.

Research from Nature Portfolio

A large retrospective study of pleomorphic xanthoastrocytoma spanning two decades has clarified clinicopathological and radiological prognostic factors. Patients with WHO grade 3 tumours, infiltrative margins, strong contrast enhancement and significant peritumoral oedema showed markedly poorer progression-free and overall survival than those with grade 2 lesions. While gross total resection emerged as a favourable determinant, multivariate analysis highlighted the overriding impact of histological grade and margin infiltration. The authors advocate for integration of molecular markers—such as BRAF V600E and TERT promoter status—into future prognostic models, underlining the heterogeneous nature of PXA and the need for personalised treatment strategies informed by combined morphological and genetic profiling.

BRAF Mutation Implications in Central Nervous System Tumors publication trend

The graph below shows the total number of articles in braf mutation implications in central nervous system tumors across all publications each year (not limited to Nature Index journals).

Technical terms

BRAF V600E mutation: A point mutation replacing valine with glutamic acid at codon 600 of the BRAF gene, resulting in constitutive kinase activation and downstream MAPK signalling.

MAPK pathway: Mitogen-activated protein kinase cascade regulating cell proliferation and survival, frequently dysregulated in oncogenesis.

Pleomorphic xanthoastrocytoma (PXA): A rare astrocytic tumour commonly driven by BRAF V600E, displaying heterogeneous prognosis and potential for anaplastic progression.

Epithelioid glioblastoma: An aggressive glioblastoma variant characterised by epithelioid morphology, frequent BRAF alterations and a propensity for leptomeningeal spread.

References

1. Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation. Acta Neuropathologica Communications (2024).
2. Exploring prognostic factors and treatment strategies for long-term survival in pleomorphic xanthoastrocytoma patients. Scientific Reports (2024).
3. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagnostic Pathology (2016).
4. Regression of BRAF V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.. Oncotarget (2019).